Unifrax Announces SiFAB™ Manufacturing Line
Unifrax, a Buffalo, New York headquartered global manufacturer of high-performance specialty materials, announced plans today to build its first large-scale SiFAB (silicon fiber anode material) manufacturing line at its north central Indiana facility that could add up to 74 new jobs by the end of 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005391/en/
SiFAB is a proprietary silicon anode battery technology which enables significantly greater energy density in lithium-ion battery systems than prevailing technologies. SiFAB is currently in advanced testing and has shown promising performance in multiple battery systems. The anode technology has successfully been tested with incremental Si loadings of greater than 40%. Along with greater energy density, SiFAB is expected to provide faster charges and longer battery life for applications including electric vehicles, portable electronics, power tools, energy grid storage and aerospace.
Unifrax is uniquely positioned to meet customer demand and develop SiFAB at scale, due to its existing manufacturing plant and infrastructure in New Carlisle. The Indiana plant will be the first to begin building SiFAB long-term manufacturing capacity. The new line is slated to create up to 20 new jobs by the end 2022, with additional growth anticipated by the end of 2023. Unifrax will have more information on open positions later this year on its website.
“SiFAB is the latest development using fiber-based technology to create step change value for customers. This transformational material represents another addition to our robust electric vehicle and battery solutions portfolio,” said John Dandolph, president and CEO, Unifrax. “Unifrax is a large, global manufacturing company introducing game changing advanced silicon anode materials that can be used in existing manufacturing processes. Our track record and proven ability to develop new and unique technologies will help transform the battery industry with SiFAB. The ability to leverage our existing facility and add new infrastructure to support SiFAB manufacturing in New Carlisle will significantly accelerate the timeline for supplying this critical material to our partners. We are appreciative of the ongoing partnership between the state of Indiana and St. Joseph County as we leverage the footprint of our existing facility to bring new jobs and opportunities to the region.”
“We designed SiFAB from its inception to be manufactured at large scale so that we could supply all market segments (EV’s, consumer electronics, power tools, and renewable storage), utilize our existing global manufacturing footprint, and deliver a product that has a high degree of quality and consistency,” said Chad Cannan, senior vice president of research and development, Unifrax.
The Indiana Economic Development Corporation offered Unifrax up to $1.1 million in conditional tax credits based on the company’s job creation plans. These tax credits are performance-based, meaning the company is eligible to claim incentives once Hoosiers are hired. St. Joseph County has also confirmed $775K in county tax incentives.
“Indiana is a leader in manufacturing, with the highest concentration of manufacturing jobs in the nation supported by 9,000 facilities across the state," said Jim Staton, interim secretary of commerce for the state of Indiana. “As new trends and technologies change the state of today’s manufacturing industry, Indiana is focused on partnering with forward-thinking companies like Unifrax to propel long-term growth in manufacturing and create quality career opportunities for Hoosiers.”
St. Joseph County Commissioner Andrew Kostielney also added, "The recent announcement by Unifrax is exciting news, not just for St. Joseph County, but for the entire region. Unifrax has long been an important manufacturing leader in the area, and this expansion indicates their commitment to our county for decades to come. Their new SiFAB line will not just create new jobs, it will also showcase the importance of green, sustainable technology."
After more than 75 years of experience in fiber-based technology and manufacturing, Unifrax is taking its first step into developing silicon fiber for the lithium-ion battery manufacturing market. With a decades-long track record of developing and supplying engineered inorganic materials at a large scale to advanced industries worldwide including electric vehicles, aerospace and chemical processing, Unifrax recently debuted two new fiber-based catalysis offerings for the automotive and industrial markets – Eco-lytic™ and FlexCat™.
To learn more about SiFAB, and to request a sample, Unifrax launched a new website introducing SiFAB with technical, manufacturing and application specific information. The new website can be found at sifab.com.
About Unifrax
Unifrax develops and manufactures high performance specialty materials used in advanced applications including high-temperature industrial insulation, electric vehicles, energy storage, filtration, and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com. For updates, follow us on Twitter, LinkedIn, and Facebook.
About Clearlake
Clearlake Capital Group, L.P. is a leading investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S. ® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $39 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.
About IEDC
The Indiana Economic Development Corporation (IEDC) leads the state of Indiana’s economic development efforts, helping businesses launch, grow and locate in the state. Governed by a 15-member board chaired by Governor Eric J. Holcomb, the IEDC manages many initiatives, including performance-based tax credits, workforce training grants, innovation and entrepreneurship resources, public infrastructure assistance, and talent attraction and retention efforts. For more information about the IEDC, visit www.iedc.in.gov.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005391/en/
Contact information
Media:
Deborah L. Myers (Unifrax) – dmyers@unifrax.com or 716.812.4802
Jennifer Hurson (Clearlake Capital) – jhurson@lambert.com or 845.507.0571
Erin Sweitzer (IEDC) – 317.296.2556 or esweitzer@iedc.in.gov
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
